No annual revenue total was found in Faeth Therapeutics, Inc.'s SEC filings.
Faeth Therapeutics, Inc. (FTH) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$20.5 million. As of Sep 30, 2026 it held $174.8 million in cash and investments and $145,000 in total debt.
Revenue
—
Net income (TTM)
$-211.36M
-775.6% vs year-ago TTM
Operating cash flow (TTM)
$-43.27M
-93.3% vs year-ago TTM
Free cash flow (TTM)
$-43.28M
-93.2% vs year-ago TTM
EPS (TTM)
$-24.72
-29.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
1.34M
-94.7% vs prior year
Net cash
$174.65M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FTH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1829802
- Former names
- Sensei Biotherapeutics, Inc. (until Jun 16, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$22.3M | -$32.6M | -$37.1M | -$50.2M | -$37.5M |
| Net income | -$21.1M | -$30.2M | -$34.1M | -$48.6M | -$36.8M |
| Diluted EPS | -$16.72 | -$24.01 | -$1.22 | -$1.58 | — |
| Operating cash flow | -$20.5M | -$24.7M | -$32.0M | -$39.0M | -$30.3M |
| Free cash flow | -$20.5M | -$24.8M | -$32.2M | -$39.3M | -$32.3M |
| Total assets | $22.9M | $45.4M | $74.4M | $118.4M | $153.2M |
| Total liabilities | $4.3M | $7.0M | $9.5M | $15.0M | $6.7M |
| Stockholders' equity | $18.6M | $38.4M | $64.9M | $103.4M | $146.5M |
| Cash and investments | $21.2M | $41.3M | $65.8M | $107.1M | $147.6M |
| Total debt | $1.5M | $3.8M | $6.2M | $8.0M | $2.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 27, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 17, 2026 | Sep 11, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
All 452 Faeth Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.